Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $83,511 | $113,968 | $215,850 |
| - Cash | $39,072 | $37,599 | $41,929 | $33,901 |
| + Debt | $36,708 | $37,690 | $38,651 | $39,577 |
| Enterprise Value | – | $83,602 | $110,690 | $221,526 |
| Revenue | $0 | $0 | $0 | $26,865 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $26,865 |
| % Margin | – | – | – | 100% |
| EBITDA | -$26,531 | -$34,746 | -$37,565 | -$45,796 |
| % Margin | – | – | – | -170.5% |
| Net Income | -$26,691 | -$26,874 | -$48,279 | -$47,472 |
| % Margin | – | – | – | -176.7% |
| EPS Diluted | -0.37 | -0.37 | -0.67 | -0.67 |
| % Growth | 0% | 44.8% | 0% | – |
| Operating Cash Flow | -$26,963 | -$34,708 | -$32,636 | -$39,702 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$26,963 | -$34,708 | -$32,636 | -$39,702 |